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Introduction
‘Ecstasy’ or 3,4-methylenedioxymethamphetamine (MDMA) is 
used as an illicit drug by subgroups of adolescents and young 
adults. Its recreational use is mainly associated with dance clubs, 
all-night ‘raves’ and house parties (Parrott et al., 2008; Winstock 
et al., 2001). Population surveys in the US reveal usage levels as 
high as 9.5% in college students (Johnston et al., 2005; Singer 
et al., 2004). In the American National Survey on drug use and 
health, Ecstasy/MDMA is found to be used more by young 
women than men (Wu et al., 2010). Neuroimaging studies of 
abstinent MDMA users reveal significantly lower levels of the 
serotonin transporter (SERT) (Erritizoe et al., 2011; Kish et al., 
2010), and are widely interpreted as suggesting serotonergic neu-
rotoxicity (Benningfield and Cowan, 2013; Parrott, 2013a; Puerta 
et al., 2009; Ricaurte et al., 2000). Recreational use of MDMA is 
also associated with various neuropsychobiological problems, 
including memory deficits (Montgomery et al., 2010; Rogers 
et al., 2009; Zakzanis and Campbell, 2006), impairments in 
higher cognitive processing (Fox et al, 2002; Parrott, 2012, 
2013b; Reay et al., 2006), sleep apnea (McCann et al., 2009), 
raised cortisol levels (Parrott, 2009; Parrott et al., 2012), psycho-
social impairment (Topp et al., 1999) and various psychiatric 
problems (Briere et al., 2012; MacInnes et al., 2000; Milani 
et al., 2004; Morgan et al., 2002; Schifano et al., 1998; Singer 
et al., 2004; Verheyden et al., 2003).
Laboratory animal studies show adverse effects of MDMA 
upon the developing foetus (Adori et al., 2010; Skelton et al., 
2008), raising concerns about potentially damaging effects when 
taken by female recreational users during pregnancy. To date, 
there has been no controlled empirical data addressing this ques-
tion, although there is some evidence of adverse birth conse-
quences (McElhatton et al., 1999; Singer et al., 2012b). To 
investigate the potential effects of foetal MDMA exposure on 
development, the US National Institute on Drug Abuse (NIDA) 
funded the Drugs and Infancy Study (DAISY). This prospective 
study monitored a group of mothers whom took recreational 
Ecstasy/MDMA while pregnant, and a control group of pregnant 
females, the other ‘polydrug’ users. The two groups were fol-
lowed over time, in order to monitor the physical development 
and psychobiological well-being of their children. Over the first 
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year of life, the children of MDMA-using mothers displayed sig-
nificantly poorer gross psychomotor skills than control group 
children (Singer et al., 2012a, 2012b). The DAISY study also 
assessed maternal well-being, using the Brief Symptom 
Inventory, a self-reporting measure of psychiatric health for non-
clinical populations, derived from the earlier Symptom Check 
List-90 (Derogatis and Nelisaratos, 1983).
This psychiatric measure was included, because previous 
research shows higher symptom profiles in abstinent Ecstasy/
MDMA users. Soar et al. (2001) reviews the medical case study 
literature, which indicated an increased risk of several psychiatric 
disorders, including depression and psychosis, in MDMA users. 
Schifano et al. (1998) noted that regular Ecstasy/MDMA users 
are at increased risk of developing various psychiatric problems, 
the most frequent being depression. MacInnes et al. (2000) found 
significantly raised Beck Depression Inventory (BDI) scores in a 
non-clinical sample of abstinent regular Ecstasy/MDMA users. 
Singer et al. (2004) found that abstinent Ecstasy users reported 
significantly higher BSI scores for anxiety, depression and obses-
sive-compulsive disorder than non-user controls. Milani et al. 
(2004) reported significant gender effects, with female Ecstasy/
MDMA users reporting higher levels of BSI anxiety, depression 
and somatization scores. Verheyden et al. (2003) investigated the 
reasons for quitting Ecstasy/MDMA: They found that most users 
in their large survey reported improved mental health after drug 
cessation. In the current DAISY, the BSI allowed us to prospec-
tively monitor the psychiatric health of our pregnant mothers and 
to investigate how any changes in drug usage were associated 
with their report of psychological distress on the BSI. Based on 
previous findings, it might be predicted that elevated psychiatric 
symptoms would be evident in mothers who are continuing 
MDMA users, whilst those who discontinue use may show 
improvements; however, given its uniqueness, and the additional 
biopsychosocial changes associated with pregnancy and mother-
hood, the aims of the study were largely exploratory.
Methods
Experimental design
The data in the current report were collected as part of the mater-
nal assessment component of DAISY, a prospective study pri-
marily exploring the effects of recreational drug use, notably 
MDMA/Ecstasy, on infant social and cognitive development 
(Moore et al., 2010; Singer et al., 2012a, 2012b). In a mixed 
design, mothers who used MDMA/Ecstasy during pregnancy 
(MDMA/Ecstasy users) were compared with those who used 
other drugs, but not MDMA/Ecstasy (Polydrug user controls), 
across measures of drug use and symptoms of mental distress, at 
four distinct time periods: the first trimester of pregnancy and at 
1, 4 and 12 months post-partum.
Participants
We prospectively recruited 96 pregnant women from the UK 
through midwife referrals, leaflets describing the study at pre-
natal clinics and advertisements in commercial pregnancy mag-
azines. We sought pregnant women whom were using 
recreational drugs during pregnancy, listing ecstasy, tobacco, 
Cannabis, alcohol and cocaine as examples. The majority of 
participants were therefore recreational ‘polydrug’ users. 
Exclusionary factors included: positive HIV status, moderate or 
severe intellectual disability, chronic medical disorder or psy-
chiatric diagnosis. In total, there were 28 mothers in the 
MDMA-exposed group, who used MDMA (and other sub-
stances) during pregnancy, and 68 non-MDMA controls (some 
of whom used substances during pregnancy, but not MDMA). 
The majority of the sample were white, married or with a part-
ner, and educated to a UK degree level. Their mean ages at the 
birth of their infants were 30.3 (SD 6.4) years of age in the 
MDMA-exposed group and 28.4 (SD 6.2) in the controls. The 
groups did not differ on basic demographic profiles. Participants 
were informed of data confidentiality and they gave written 
informed consent. The study protocol was approved by ethics 
committees from the University of East London, UK; Case 
Western Reserve University, US; and the National Health 
Service, UK. For a fuller description of the participant sample 
and screening procedures, see Singer et al. (2012a).
Drug usage
All women were individually interviewed about their substance 
use by fully trained female research assistants. The interview was 
an adaptation of the Maternal Post-Partum Interview, which was 
developed for earlier studies of maternal cocaine exposure 
(Singer et al., 2002). Interview questions covered substances 
commonly used in the UK and were based on the University of 
East London Recreational Drug Usage Questionnaire (Parrott 
et al., 2001). The list of drugs included tobacco/cigarettes, alco-
hol, Cannabis, Ecstasy/MDMA, amphetamine, cocaine, LSD, 
benzodiazepines, hallucinogenic mushrooms, ketamine and opi-
ates. It may be noted that mephedrone (m-cathinone or ‘m-cat’) 
was not on this list, since the DAISY study was undertaken 
before ‘m-cat’ was used as a recreational drug (Schifano et al., 
2011). Mean usage for each drug per week was calculated by 
multiplying the frequency of use with the amount taken per occa-
sion. The MDMA user group comprised women who reported 
taking MDMA during pregnancy or in the month prior to preg-
nancy. Those who reported MDMA use prior to this time were 
categorized as non-users, because the study was designed to 
assess foetal drug exposure.
Assessment battery
The study included a comprehensive battery of assessment meas-
ures, covering various aspects of child behaviour and physical 
health indices, maternal activities and psychological well-being 
(Singer et al., 2012a,2012b). This report describes the findings 
from the Brief Symptom Inventory (BSI) (Derogatis and 
Nelisaratos, 1983). This questionnaire comprises 53 self-rating 
questions across nine psychiatric subscales, for: depression, anxi-
ety, phobic anxiety, hostility, somatic complaints, obsessive-
compulsive behavior, interpersonal sensitivity, paranoid ideation 
and psychosis/schizophrenia. The summary measure, the General 
Severity Index (GSI), provided a general index for overall psy-
chiatric distress. The assessments covered four occasions: first 
trimester of pregnancy, 1 month post-partum, 4 months post-
partum and 12 months post-partum.
Statistical analyses
Data that were positively skewed were transformed using natu-
ral logarithm, prior to analysis; however, the means and SDs are 
reported for the untransformed scores. Bivariate correlations 
were employed to calculate the inter-relationships between vari-
ables. Multicollinearity was assessed using tolerance and vari-
ance inflation factor. We implemented repeated measures 
Analysis of Variance (ANOVA), using a mixed model approach, 
by SAS Proc Mixed with maximum estimation method, to com-
pare the substance use for both groups, MDMA-users during 
pregnancy (n = 28) and non-users of MDMA during pregnancy 
(n = 68), at the four different assessment times (during preg-
nancy, 4 weeks after birth, 12 weeks and 52 weeks). As noted 
earlier, both groups contained polydrug users of various sub-
stances, both legal (tobacco and/or alcohol), and illegal 
(Cannabis, amphetamine and/or cocaine) (Moore et al., 2010). 
Because the dependent variables were repeated measures and 
correlated within subjects, we used an unstructured covariance 
matrix to account for these correlated responses. We included 
interaction terms between drug groups and time, to test for 
homogeneity of MDMA effects over time. For all BSI outcome 
measures, we employed repeated measures Analysis of 
Covariance (ANCOVA). The covariates included other sub-
stance usage that differed by MDMA status at p < 0.10, and were 
correlated with the given outcome at p < 0.10 on at least two 
time points: They were then entered into the longitudinal model. 
Different sets of covariates were adjusted on each psychological 
outcome, and included demographic variables and use of all 
other drugs.
Results
The socioeconomic and educational profiles of mothers enrolled 
in the study are described more fully elsewhere (Singer et al., 
2012a). In brief, the cohort was primarily white, married or in 
a stable relationship, and represented a wide range of socioeco-
nomic backgrounds that included many from middle and 
higher psychosocial groupings. The MDMA-using mothers 
and polydrug control mothers were well matched on most varia-
bles (Singer et al., 2012a). Table 1 describes the group mean 
weekly rates of usage for the five main types of drug used: alco-
hol, nicotine/cigarettes, Cannabis/marijuana, cocaine and 
Ecstasy/MDMA. Other psychoactive drugs were taken by a few 
individuals, and those data are described more fully elsewhere 
(Moore et al., 2010).
A mixed ANOVA was conducted with group as the between-
conditions factor and time as the within-conditions factor. The 
between-groups ANOVA revealed that the two groups did not 
differ in overall use of alcohol, cigarettes, Cannabis nor cocaine; 
although the cocaine group effect was statistically borderline 
(Table 1, where the group effect for Ecstasy was not calculated, 
because it was used to define these two groups).
The ANOVA for the time factor was significant for all five 
drugs (all p = 0.01 or smaller), with lower rates of usage during 
the weeks after giving birth. The ANOVA grouped by time inter-
actions were significant for alcohol and cigarettes (F[3,88] = 
4.06; p < 0.005 and F[3,88] = 3.61; p < 0.02 respectively), with 
the MDMA mothers using slightly more than the controls during 
the first trimester of pregnancy, but slightly less than controls 
across all the other time periods (Table 1). The group x time 
interaction was not significant for Cannabis, though Ecstasy/
MDMA-using mothers appeared to be taking slightly more 
Cannabis than controls, across all time points (Table 1). The 
group x time interaction was significant for cocaine (F[3,88] = 
3.48; p < 0.05), with the most usage during the first session by 
Ecstasy users (Table 1).
The Ecstasy-using mothers reported taking an average of 0.84 
Ecstasy tablets/week during the first trimester of pregnancy. In 
terms of previous lifetime usage (Singer et al., 2012a), they 
reported first using Ecstasy at a mean age of 20.2 years (range 14 
– 29 years), had taken it on an average of 171 times/lifetime
(range 6 – 936 times), and typically ingested an average of 3
tablets per occasion (range 1 – 8 tablets), with an average maxi-
mum usage per occasion of 7.4 Ecstasy tablets (range 2 – 20 tab-
lets). Turning to their usage around the time of pregnancy, the
mean total amount of MDMA used during pregnancy and in the
month prior was 25 tablets (range 0.45 – 180 tablets). Within the
Table 1. Ecstasy/MDMA, alcohol, cigarettes, marijuana/Cannabis and cocaine usage patterns for 28 mothers whom took Ecstasy/MDMA during 
pregnancy and a control group of 68 polydrug users during pregnancy. Drug values represent mean weekly rates of usage, during first trimester of 
pregnancy and three times up to 1 year post-partum.
Drug type Maternal group First trimester of 
pregnancy
1 month 
post-partum
4 months post-
partum
12 months 
post-partum
ANOVA
Group Time (GxT)
Ecstasy
(tablets)
Polydrug controls
Ecstasy users
0.00 +/- 0.00
0.82 +/- 1.57
0.00 +/- 0.00
0.01 +/- 0.03
0.02 +/- 0.16
0.03 +/- 0.13
0.01 +/- 0.02
0.06 +/- 0.09
No between-
group analysis
< .0001 -
Alcohol
(units)
Polydrug controls 6.94 +/- 16.90 3.11 +/- 10.66 6.48 +/-10.89 13.75 +/-24.02 n.s .0001 .02
Ecstasy users 12.07 +/- 16.62 1.33 +/- 1.80 5.30 +/- 5.70 6.01 +/- 5.99
Cigarette
(numbers)
Polydrug controls 28.15 +/-48.10 23.45 +/- 50.13 27.27 +/- 40.02 32.88 +/-48.14 n.s .0001 .003
Ecstasy users 44.78 +/- 49.50 17.88 +/-30.79 17.59 +/- 22.23 28.68 +/-34.37
Cannabis
(joints)
Polydrug controls 7.44 +/- 19.24 3.36 +/- 7.87 3.12 +/-7.51 5.26 +/-12.95 n.s .0001 n.s.
Ecstasy users 10.28 +/- 20.81 6.86 +/- 17.36 6.20 +/- 16.12 7.35 +/-15.46
Cocaine
(grams)
Polydrug controls 0.02 +/-0.18 0.001 +/- 0.01 0.01 +/- 0.07 0.02 +/- 0.14 .057 .013 .03
Ecstasy users 0.23 +/- 0.85 0.01 +/- 0.04 0.02 +/- 0.06 0.02 +/- 0.05
MDMA: ‘Ecstasy’ or 3,4-methylenedioxymethamphetamine.  
Note: Units refer to UK units of alcohol (1 unit = 10ml or 7.9 grams of alcohol); n.s.= non-significant.
polydrug control group, several women had used ecstasy/MDMA 
previously, but were currently non-users (Singer et al., 2012a).
The Brief Symptom Inventory findings are summarized in 
Table 2. The main focus of interest here is the difference in psy-
chiatric well-being between the first and last sessions. Over that 
time period, the control group mothers showed a significant 
decline in BSI symptoms for somatization (p < 0.001) and anxi-
ety (p < 0.05). Over the same period, the Ecstasy/MDMA sub-
group mothers showed significant declines in BSI symptoms for 
(Table 2): somatization (p < 0.001), depression (p < 0.05), inter-
personal sensitivity (p < 0.05) and obsessive-compulsive disor-
der (p < 0.05).
Discussion
The young mothers in the DAISY study provided a unique cohort 
in several respects. Although recreational polydrug users, they 
were predominantly middle class with middle socioeconomic 
status, and in stable interpersonal relationships; hence, unlike 
many studies of illicit drug users, they were not socially disad-
vantaged. The study covered an extended time period of nearly 
2 years, and is to our knowledge the first study of pregnant 
Ecstasy/MDMA users. The cohort of almost 100 mothers was 
comparatively large, especially for a prospective study with 
repeated assessments. One of the main aims of the DAISY study 
was to investigate the effects of recreational Ecstasy/MDMA 
usage during pregnancy on subsequent child development. The 
main findings were that the children of Ecstasy/MDMA using 
mothers displayed significant psychomotor problems in compari-
son to control group children, as described elsewhere (Singer 
et al., 2012a, 2012b).
The study design allowed us to monitor changes in maternal 
reports of psychological well-being over time, in particular any 
alterations in their psychiatric status from the first to the last assess-
ment. In this respect, both groups of mothers showed significantly 
higher somatization scores during the first trimester of pregnancy, 
when compared to 12 months post-partum (Table 2). The control 
group mothers also showed a significant reduction in BSI 
Table 2. Psychiatric symptoms on the Brief Symptom Inventory during and after pregnancy for 28 mothers whom took Ecstasy/MDMA during 
pregnancy and for a non-user control group of 68 mothers whom took other drugs during pregnancy (polydrug controls).
Group Time 1:
Early-mid Pregnancy
Time 2:
Postpartum
1 month
Time 3:
Postpartum
4 months
Time 4:
Postpartum 
12 months
Paired
comparison,
Time 1 vs. 4
General symptoms
Polydrug controls 0.61 0.51 0.54 0.50 -
Ecstasy users 0.79 0.71 0.81 0.56 -
Depression
Polydrug controls 0.50 0.45 0.57 0.50 -
Ecstasy users 0.87 0.74 0.80 0.51  p < 0.05
Anxiety
Polydrug controls 0.55 0.46 0.48 0.34 p < 0.05
Ecstasy users 0.74 0.68 0.69 0.56 -
Hostility
Polydrug controls 0.71 0.65 0.66 0.59 -
Ecstasy users 0.74 0.80 1.24 0.55 -
Psychoticism
Polydrug controls 0.31 0.25 0.36 0.30 -
Ecstasy users 0.52 0.51 0.62 0.42 -
Somatization
Polydrug controls 0.58 0.36 0.27 0.32 p < 0.001
Ecstasy users 0.78 0.50 0.51 0.39 p < 0.01
Paranoid ideation
Polydrug controls 0.61 0.48 0.64 0.66 -
Ecstasy users 0.75 0.70 066 0.73 -
Obsessive-compulsive
Polydrug controls 1.08 1.10 0.98 0.89 -
Ecstasy users 1.20 1.23 1.31 0.82 p < 0.05
Interpersonal sensitivity
Polydrug controls 0.74 0.64 0.64 0.73 -
Ecstasy users 0.92 0.85 0.96 0.57 p < 0.05
Phobic anxiety
Polydrug controls 0.27 0.20 0.30 0.20 -
Ecstasy users 0.47 0.39 0.52 0.37 -
MDMA: ‘Ecstasy’ or 3,4-methylenedioxymethamphetamine.
symptoms of anxiety, while the MDMA subgroup showed a very 
similar trend (Table 2). The first trimester of pregnancy is a period 
of pronounced somatic body changes, and so intuitively explains 
the higher somatization scores in both groups of women. Thus, the 
reduced BSI somatization scores 1 year post-partum may reflect a 
return to physical normality in both groups of women. The first tri-
mester of pregnancy is also a period of general anxiety, with natural 
concerns and worries over becoming pregnant. This may help to 
explain the comparatively higher BSI anxiety scores during the first 
trimester, and the reduced scores at the final session (Table 2).
The Ecstasy/MDMA-using mothers showed a different pattern 
of change, compared to the controls, on three BSI subscales, for: 
depression, obsessive compulsive disorder and interpersonal sensi-
tivity (Table 2). The Ecstasy subgroup mothers reported feeling 
more depressed than control mothers at the first time point, with a 
statistically borderline between-group difference (p = 0.058, two-
tail). At 1 year post-partum, the depression scores for the MDMA 
group had reduced significantly (p < 0.05), to become almost iden-
tical to the control group (Figure 1). The BSI depression scores for 
the control group mothers remained broadly unchanged over this 
period. The MDMA group also showed significant BSI reductions 
for interpersonal sensitivity and obsessive-compulsive disorder 
(Table 2). In order to examine the potential reasons for these 
changes, the changing patterns of drug usage over time should be 
noted. The Ecstasy/MDMA-group mothers had reduced their usage 
of Ecstasy to near-zero after giving birth (Table 1); hence, 1 year 
post-partum they had become former MDMA users. Their BSI 
improvement may reflect this cessation of Ecstasy/MDMA use.
There is extensive empirical literature demonstrating higher 
rates of psychiatric distress in current Ecstasy/MDMA users and 
psychiatric gains following drug cessation. Schifano et al. 
(1998) gave structured psychiatric interviews to young Ecstasy/
MDMA users at an addiction centre in Italy, reporting that 
around one-half the sample reported symptoms of psychiatric 
distress, especially depression, but also psychotic disorder, 
impulse control disorder, bulimia and panic disorder. MacInnes 
et al. (2000) compared young Ecstasy/MDMA users and poly-
drug controls, with participants screened to exclude anyone with 
a prior psychiatric history. On the BDI, Ecstasy users displayed 
significantly higher depression scores than the non-MDMA-user 
controls. In a survey of over 700 young people from the UK and 
Italy, the SCL-90 symptom profiles of the Ecstasy polydrug users 
were significantly higher than the non-MDMA-user controls 
(Parrott et al., 2001). In a US study of abstinent MDMA users 
compared to non-user controls who visited raves (Singer et al., 
2004), the Ecstasy/MDMA users reported significantly higher 
BSI depression, anxiety and obsessive-compulsive disorder than 
the controls. Brière et al. (2012) prospectively found that taking 
up recreational Ecstasy/MDMA in Canadian schoolchildren led 
to increased depression 1 year later. There are also indications 
that psychiatric health can improve after quitting. Morgan et al. 
(2002) report that current Ecstasy/MDMA users have elevated 
scores on many SCL-90 subscales, whereas former Ecstasy users 
have scores intermediate between the current Ecstasy users and 
the non-user controls. Verheyden et al. (2003) interviewed for-
mer users about their reasons for quitting Ecstasy/MDMA. Over 
one-half reported that ‘mental health problems due to MDMA’ 
were the main reason for quitting drug use: That using Ecstasy 
led to feelings of anxiety and depression, and that they feared for 
their mental health in the longer-term. Over 70% of those partici-
pants report ‘improved mental health’ after quitting.
An important potential confounder for Ecstasy/MDMA 
research is the use of other recreational drugs, because many 
Ecstasy users take a range of psychoactive drugs (Parrott et al., 
2001; Parrott et al., 2007; Sala and Braida, 2004; Scholey et al., 
2004). In the DAISY study, we collected systematic drug usage 
data at all four time points. As noted above, the use of Ecstasy/
MDMA was largely restricted to the first trimester of pregnancy. 
In contrast, the use of alcohol, tobacco and Cannabis continued 
throughout the study. There is some indication of a decline in all 
drug use in the Ecstasy/MDMA group, with significant group/
time interactions for alcohol and cigarettes, especially. As such, it 
could be argued that the depression effect in the Ecstasy/MDMA 
users was in part due to changes in alcohol and/or cigarette use, 
as both have been linked to higher depression scores (Munafo 
and Araya, 2010; Raimo and Schuckit, 1998); however, usage 
rates at baseline were broadly similar to 1 year post-partum, in 
both groups (Table 1). Hence, the changes in psychiatric status 
noted here (Table 2) cannot easily be attributed to alcohol, 
tobacco, nor Cannabis usage; however, the usage pattern for 
cocaine was very similar to Ecstasy/MDMA, with almost total 
cessation after the first trimester (Table 1). Thus, the selective 
reductions in particular psychiatric symptoms may reflect the 
cessation of Ecstasy/MDMA and/or cocaine usage.
There are several ways in which central nervous system (CNS) 
stimulant drugs like MDMA can enhance psychiatric distress. In 
acute terms, MDMA is a powerful mood intensifier, but it can 
boost positive and negative-feeling states; thus, increased levels of 
happiness and euphoria are often accompanied by emotional ten-
sion. This intensification of both positive and negative moods is 
reported in studies of recreational users and in placebo-controlled 
laboratory studies (Kirkpatrick et al., 2012; Parrott et al., 2011).
It is also noted in the psychotherapeutic situation: Two clients 
undergoing ‘MDMA-assisted psychotherapy’ experienced a 
resurgence of previous psychiatric problems following acute 
MDMA administration, with one client needing psychotherapy 
Figure 1. Brief Symptom Inventory ratings of depression during the 
first trimester and at 12 months post-partum, in women reporting 
MDMA/Ecstasy use during pregnancy, and in control women taking 
other recreational drugs during pregnancy.
*p < 0.05; Error bars indicate ±1 SE.
MDMA: ‘Ecstasy’ or 3,4-methylenedioxymethamphetamine.
for a year afterwards, to resolve the MDMA-induced problems 
(Greer and Tolbert, 1986; Parrott, 2007). In sub-acute terms, 
MDMA use is typically followed by a period of neurochemical 
recovery, when low moods and feelings of depression predomi-
nate; indeed, the ‘mid-week blues’ can often last for several days 
and may reach clinical levels in some individuals (Curran and 
Travill, 1997). Because the positive mood intensification under 
MDMA is brief (several hours), and the post-MDMA period of 
mood recovery is more prolonged (several days), the average 
weekly mood of Ecstasy users will often be lower than in non-
users (Parrott and Lasky, 1998). Such effects are supported in the 
animal literature by the acute and subacute impact of MDMA on 
5-HT, notably, delays in recovery of this transmitter in brain
regions regulating emotion (Colado et al., 1999); and similar pat-
tern reductions in other functional serotonergic factors, such as
SERT and tryptophan hydroxylase (Adori et al., 2011).
In addition, in chronic terms, abstinent Ecstasy/MDMA users 
report higher levels of stress and lower levels of happiness than 
non-user controls (Scholey et al., 2011). When used repeatedly, 
sympathomimetic drugs such as amphetamine, cocaine and MDMA 
can adversely affect the  hypothalamic pituitary adrenal (HPA)  axis 
and impair homeostatic control via the stress hormone cortisol 
(Seyle, 1955). Indeed, acute MDMA use can increase cortisol levels 
by 800% in young dance club attendees (Parrott et al., 2008). While 
sub-chronically, recent Ecstasy/MDMA users display a 400% 
increase of cortisol in 3-month hair samples (Parrott et al., 2012); 
hence, recreational MDMA is both an acute and chronic stressor for 
the HPA axis (Parrott, 2009). There is also evidence that premorbid 
factors may heighten the likelihood of clinical problems in disad-
vantaged individuals; this interactive ‘diathesis-stress’ model for 
recreational Ecstasy/MDMA is described more fully elsewhere 
(Parrott, 2006). The possible causative factors (including neurotox-
icity, recovery and/or HPA axis changes) for the effects observed 
here in the current data, and in much of the literature, still need 
considerable further empirical investigation.
There are several limitations to the DAISY study. We relied on 
self-reported drug use and cannot therefore be certain that ‘Ecstasy’ 
comprised ‘MDMA’; however, data collection occurred during 2003 
– 2006, which corresponded with a period of high MDMA purity in
the UK. This was apparent in another study we undertook during
2006, which shows very high concordance between self-rated
Ecstasy and MDMA use as detected in saliva samples (Parrott et al.,
2008). The second weakness was the absence of a non-user control
group, because many studies have found that polydrug users are
more impaired than non-users (Morgan et al., 2002; Parrot et al.,
2001). Thirdly, although the DAISY study was designed as a pro-
spective study, this was only partially achieved (Moore et al., 2010);
hence, missing data point’s retrospective ratings were sometimes
required (Singer et al., 2012a). Finally, the overall BSI difference
scores were not large (Table 2); however, we were not expecting
strong drug effects, because our participants were psychiatrically
normal and their use of most drugs was similar at the first and last
time points. Furthermore, although the group mean reduction of 0.2
on the BSI depression subscale may have been comparatively slight,
it would still be beneficial for the individual user. It would also
reduce the likelihood of individuals with prior vulnerability factors
from developing more severe psychiatric problems (Parrott, 2006).
In summary, recreational stimulant drugs such as MDMA, 
cocaine and amphetamine, are well-known to be associated with 
enhanced psychiatric distress. The DAISY study found that 
women who took Ecstasy/MDMA during their first trimester of 
pregnancy reported slightly higher psychiatric symptom profiles 
than a control group of polydrug-using mothers. One year after 
giving birth, their psychiatric symptom profiles improved to val-
ues near the control group (Table 2 and Figure 1). The main 
explanatory factor proposed for this gain in psychiatric well-
being was the cessation of Ecstasy/MDMA usage, coupled with 
the parallel reduction in cocaine use. Hence, this study confirmed 
that a reduction in stimulant drug usage can have beneficial 
effects on well-being. Finally, we should also note that the 
DAISY study investigated the effects of MDMA use during preg-
nancy on the child’s subsequent development. It reveals that the 
children of MDMA-using mothers have various impairments in 
gross psychomotor skill (Singer et al., 2012a,2012b); hence, an 
important message for young females and their partners is to stop 
taking MDMA before pregnancy. This will protect the develop-
ing child and enhance maternal well-being.
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